Are GlaxoSmithKline plc shares a bargain after FY2017 results?

GlaxoSmithKline plc (LON: GSK) currently yields 6.1% and trades on a P/E of 11.8. Does that make the shares a ‘buy’?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 giant GlaxoSmithKline (LSE: GSK) reported full-year results for FY2017 yesterday. Let’s take a closer look at the results and examine the investment case for the healthcare giant. Are the shares a bargain at current levels?

FY2017 results

GSK’s revenue for the period increased 8% (3% at constant currency) to £30.2bn. This was slightly ahead of analysts’ estimates. Sales grew across all three divisions, with the Vaccines division putting in the strongest performance with growth of 12% (6% constant currency).

Adjusted earnings per share came in at 111.8p, growth of 11% (4% constant currency) and the full-year dividend was maintained at 80p per share. CEO Emma Walmsley described the results as “encouraging.”

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Investment case

I can see both a bull case and a bear case for buying Glaxo shares right now.

On the bull side, the shares look cheap, and the dividend yield is high. GSK has slumped from above 1,700p in June last year to 1,320p today. That leaves the stock trading on a trailing P/E ratio of just 11.8. Furthermore, the dividend yield looks compelling, at 6.1%. When you consider that it’s hard to get more than 1% per year from a savings account, a yield of over 6% is tempting.

Also, there’s the world’s ageing population to keep in mind. It’s something I wrote about here recently. The global population is getting older. As a result, demand for healthcare products should remain buoyant over the long term. Glaxo is looking to improve its pharmaceuticals business and strengthen its pipeline, and in the long run, should be able to capitalise on this theme.

On the bear side, there are several issues that investors need to be aware of.

In the near term, there are concerns over profitability. Much of this is based around the timing and impact of possible generic competition to GSK’s asthma drug Advair.

Glaxo yesterday advised that in the event of no competition in the US this year, adjusted earnings should be between 4% to 7% higher at constant currency. However, in the event that a generic competitor to Advair is introduced mid-year, adjusted earnings could fall 3% at constant currency. Both scenarios reflect the benefit of the recent US tax reform.

Dividend prospects 

Many investors are also concerned about the dividend. Yesterday, the company advised that shareholders should continue to expect a payout of 80p for 2018. It also said that it recognises the importance of dividends to shareholders.

However, the healthcare giant advised that the dividend will not be increased until free cash flow cover reaches 1.25-1.50 times. Given that free cash flow for 2017 was £3.4bn and the dividend cost the company £3.9bn (a ratio of 0.87), dividend growth looks some way off. Furthermore, a potential consumer health acquisition, such as that of Pfizer, could put a strain on Glaxo’s ability to pay its dividend going forward.

Weighing up both sides, it’s hard to call the investment case for Glaxo right now. From a pure income-investing perspective, there are better dividend stocks out there, in my view. However, from a long-term, tuck-away-for-the-future angle, GSK could have potential.

Our best passive income stock ideas

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

After collapsing 28% today, are Bunzl shares too cheap to ignore?

A poor trading statement has sent Bunzl shares to multi-year lows. Could now be a good time to consider investing…

Read more »

Investing Articles

These 5 stocks could earn £1,600 of annual passive income in a £20,000 ISA

Harvey Jones shows how to generate a high and rising passive income by buying a balanced mix of high-yielding FTSE…

Read more »

Young woman holding up three fingers
Investing Articles

3 things I like about Greggs shares

Greggs shares have tumbled by more than a third over the past year. But this writer has no plan to…

Read more »

artificial intelligence investing algorithms
Investing Articles

Nvidia stock: beware the bear market rally

Andrew Mackie argues that investors should tread carefully before investing in Nvidia stock, as the worst of the sell-off could…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

Up 73% in one year, is this the best value stock in the FTSE 100?

A brilliant run of form suggests this FTSE 100 giant should no longer make the cut as a value stock.…

Read more »

Investing Articles

The best could yet be to come for UK shares! I’m buying these ones

Amid ongoing stock market turbulence, this writer's been adding selected UK shares to his portfolio. Here's why and what he…

Read more »

Top Stocks

4 UK stocks trading well below book value to consider buying

Sometimes, it pays to be contrarian: who says the UK market has priced a stock precisely right, anyway?

Read more »

Investing Articles

The S&P 500’s 12% off its highs. Is now a good time to buy US shares for an ISA?

Right now, a lot of British investors are wondering whether it’s a good time to buy US shares. Here, Edward…

Read more »